Spima TherapeuticsSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001
GourmeyThe EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority when recommending novel food products for market authorisation.
As a Contract Development and Manufacturing Organization (CDMO), mAbxience is committed to advancing biologics production and to ensuring that patients receive life-saving treatments faster and with uncompromising quality.